Cerebral Vasospasm – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Cerebral vasospasm is a state in which the blood vessels in the brain constrict, reducing blood flow to the brain and causing brain tissue death. The Circle of Willis, a place at the base of the brain that connects the large arteries in the brain, is the most commonly involved vessel. This condition typically occurs in patients following a subarachnoid hemorrhage, a type of brain bleed caused by a ruptured aneurysm. Cerebral vasospasm affects up to 75% of patients who survive a subarachnoid hemorrhage. However, only 30% of these are symptomatic in the form of cognitive deficits. Intracranial spasm's arterial contraction typically develops a few days after the rupture of an intracranial aneurysm and lasts 2 to 3 weeks. Symptomatic vasospasm was independently associated with reduced instrumental activities of daily living, cognitive impairment, and poor quality of life in our study, but not with death or severe disability. DCI appears to be both the most inclusive and clinically meaningful definition for capturing the adverse effects of vasospasm after SAH. Once the disease is identified, treatment options include raising blood pressure to force blood perfusion to the brain and angiography. Depending on the rigor and location of the vasospasm, a physician can use angiography to deliver medicine to the arteries and balloon angioplasty to dilate the arteries.

 

Cerebral vasospasm has been estimated to occur in `50% of patients with aneurysmal subarachnoid hemorrhage (aSAH). Approximately 40,000 North American patients experience aSAH each year. It has been estimated that close to 50% of patients suffering from aSAH die before reaching medical care.

Symptomatic vasospasm occurred in 16% of patients, delayed cerebral ischemia in 21%, angiographic vasospasm in 31%, and TCD spasm in 45%. Both symptomatic vasospasm and DCI were highly correlated with angiographic and TCD spasms.

 

The competitive landscape of Cerebral Vasospasm includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Cerebral Vasospasm across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cerebral Vasospasm Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Cerebral Vasospasm – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Clazosentan      Idorsia Pharmaceuticals Ltd.      Phase 2

2          Sodium nitrite    Hope Pharmaceuticals   Phase 2

 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more